Business Wire

PLURAL

28.6.2022 09:02:27 CEST | Business Wire | Press release

Share
Founders launch Plural: a €250m fund for fellow ‘Unemployables’ building Europe’s next generation of tech companies

Plural , a new investment platform started by the founders and backers of Europe’s most significant tech companies, has unveiled today a €250m early stage venture fund (Plural Platform SCSp RAIF, “Plural ”) to back the next generation of founders with global ambitions.

Set up by Ian Hogarth, Khaled Heloui, Sten Tamkivi and Taavet Hinrikus - with other recognised founders who will announce themselves soon - Plural is a scalable investment platform whose investors are exclusively former founders and operators with decades of company building experience.

Plural was founded because the Plural founders saw that across Europe the vast majority of investors lacked experience of building tech businesses. In Europe just 8% of investors are former operators, in contrast to more than half of tech investors in the US. Plural’s founders believe that the scar tissue from building tech companies is invaluable in helping the next generation of founders to build companies with global potential.

Plural’s intention is to be a more hands-on investor, with a focus on leading early stage rounds between €1 and €10m.

The Investment Manager’s investment committee have commented as follows:

Taavet Hinrikus, co-founder of Wise, said: “We’re the investors we would have liked to have when we were building our own companies. Founding a company is a craft and the best way to learn that craft is to work alongside those who have done it before.”

Ian Hogarth said: ‘We call experienced founders 'unemployables', because once you've experienced the intense authorship that comes with creating something new it's hard to work for anyone again. Plural was created to give unemployables a place to call home and put their entrepreneurial energy behind missions and founders they deeply believe in.”

Khaled Helioui said: “So much opportunity is left untapped today as exceptional founders often fail to meet standard investors’ pattern recognition criteria. Sadly investors lack the risk appetite needed to fulfill founders’ ambitions and consequently the full impact founders seek can not be realised. By changing the funding mechanisms that act as conservative gatekeepers today we can unlock so much potential.”

Sten Tamkivi said: “We are huge optimists for the potential of technology coming from Europe which can benefit the whole world, as well as improve the lives of people across the continent. We’ve already seen the real impact a well-funded startup scene can have on economies in small countries like Estonia — now it is time to scale this GDP level impact across the whole of Europe."

Between them Taavet, Sten, Ian and Khaled have founded four startups - Wise, Songkick, Teleport and Certific - and played a significant role in building three companies, including Skype, Bigpoint and Topia. All four operators turned investors have also been angel investing for years, with significant success. Companies in their portfolio include Deliveroo, Hopin, Pipedrive, Chorus, Uber, Zego and Bolt. As Plural, they have already invested in 14 companies including Feather , NFTport an NFT infrastructure company, energy storage company Field , metaverse company Ready Player Me and student banking challenger MOS .

About Plural : Set up by founders for founders, Plural is a €250m investment platform which is investing early stage venture capital in exceptional European tech companies. Its investors with scar tissue support founders to build tech companies that can make a GDP impact. https://pluralplatform.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye